Theravance Biopharma, Inc. (NASDAQ:TBPH) Position Increased by Geode Capital Management LLC

Geode Capital Management LLC raised its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 5.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 330,280 shares of the biopharmaceutical company’s stock after buying an additional 18,177 shares during the period. Geode Capital Management LLC owned about 0.62% of Theravance Biopharma worth $12,160,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Theravance Biopharma by 4.2% in the first quarter. Vanguard Group Inc. now owns 3,080,296 shares of the biopharmaceutical company’s stock worth $113,417,000 after buying an additional 125,223 shares in the last quarter. Marshall Wace North America L.P. purchased a new stake in Theravance Biopharma during the first quarter worth approximately $21,862,000. MARSHALL WACE ASIA Ltd purchased a new stake in Theravance Biopharma during the first quarter worth approximately $21,862,000. Woodford Investment Management Ltd boosted its stake in Theravance Biopharma by 1.9% in the first quarter. Woodford Investment Management Ltd now owns 10,705,108 shares of the biopharmaceutical company’s stock worth $393,948,000 after buying an additional 197,500 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in Theravance Biopharma by 11.6% in the first quarter. Legal & General Group Plc now owns 15,713 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 1,631 shares in the last quarter. Institutional investors own 82.77% of the company’s stock.

Shares of Theravance Biopharma, Inc. (TBPH) traded down 0.94% on Friday, hitting $27.40. 396,985 shares of the stock traded hands. Theravance Biopharma, Inc. has a 52 week low of $23.15 and a 52 week high of $43.44. The stock has a 50 day moving average price of $33.89 and a 200-day moving average price of $35.36. The stock’s market cap is $1.47 billion.

ILLEGAL ACTIVITY WARNING: This piece was originally published by BNB Daily and is the property of of BNB Daily. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/geode-capital-management-llc-acquires-18177-shares-of-theravance-biopharma-inc-nasdaqtbph-updated-updated-updated.html.

A number of brokerages recently weighed in on TBPH. Cantor Fitzgerald set a $55.00 target price on shares of Theravance Biopharma and gave the stock a “buy” rating in a research note on Wednesday. Evercore ISI initiated coverage on shares of Theravance Biopharma in a research note on Wednesday. They set an “outperform” rating and a $45.00 price objective for the company. BidaskClub downgraded shares of Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. ValuEngine downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Needham & Company LLC restated a “buy” rating on shares of Theravance Biopharma in a research note on Wednesday, August 2nd. Four equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Theravance Biopharma presently has a consensus rating of “Hold” and an average price target of $41.63.

In related news, CEO Rick E. Winningham bought 10,000 shares of the stock in a transaction dated Friday, August 11th. The stock was purchased at an average cost of $24.50 per share, with a total value of $245,000.00. Following the completion of the purchase, the chief executive officer now owns 866,377 shares of the company’s stock, valued at $21,226,236.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Henrietta Fore bought 6,000 shares of the stock in a transaction dated Friday, August 11th. The shares were bought at an average cost of $23.99 per share, with a total value of $143,940.00. Following the completion of the purchase, the director now directly owns 24,000 shares of the company’s stock, valued at approximately $575,760. The disclosure for this purchase can be found here. Insiders own 6.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply